The Impact of Antimicrobial Treatment for Asymptomatic Bacteriuria in Renal Transplant Patients
NCT ID: NCT02113774
Last Updated: 2014-04-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
INTERVENTIONAL
2014-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Asymptomatic Bacteriuria & Risk of Urinary Tract Infection in Renal Transplants
NCT01349738
A Randomized Control Trial of Antibiotic Treatment Duration For Asymptomatic Bacteriuria After Kidney Transplantation
NCT02575495
Efficacy of 7 Days Versus 14 Days of Antibiotic Therapy for Acute Pyelonephritis in Kidney Transplant Recipients, a Multicentre Randomized Non-inferiority Trial.
NCT05597540
Asymptomatic Bacteriuria in Early Kidney Transplantation Follow up
NCT04333602
Treatment Chronic UTI Post Kidney Transplant
NCT05967130
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
TREATMENT
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
no therapy
No interventions assigned to this group
antimicrobial treatment according to in-vitro susceptibility
antimicrobial treatment according to in-vitro susceptibility
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
antimicrobial treatment according to in-vitro susceptibility
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Positive urine culture defined as ≥ 105 colony forming units (CFU) per milliliter of a known single pathogen.
Exclusion Criteria
* Active infections in another site
* Leucocytosis (WBC \>18.000K/micl) or leucopenia (WBC \< 3.000 K/micl)
* Elevation of serum creatinine of more than 15% of its baseline level
* Obstructive or other urological complications following transplantation as known foreign device (stent/double-J-Cath, any catheter) in the urinary tract system, known obstruction of the transplanted kidney, indwelling or intermittent catheterization
* Pregnant or lactating women.
* Candidates to invasive urologic procedures.
* Inability to return for regular follow up.
* Previous enrollment in this study.
* Patients who incapable of giving informed consent.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Rabin Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ruth Rahamimov
head of transplant investigator service
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
7687
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.